Teva is eyeing $2.5bn in Austedo sales in 2027

Teva is eyeing $2.5bn in Austedo sales in 2027

Source: 
Pharmaphorum
snippet: 

The management of Israeli pharma group Teva has laid out its strategy for a return to growth after a challenging few years, with a greater emphasis on innovative medicines and a focus on complex, higher value products in its generics business.